Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients.

ABSTRACT:

Introduction

A new type of immune cell transplantation called allogeneic NK cell infusion is proposed as a potential universal off-the-shelf cell product for adoptive immune cell therapy in hematologic malignancies.

Design

A multicentral phase I non-randomized clinical trial was conducted to assess the safety, feasibility, and potential efficacy of adoptively infused NK cells in patients with refractory/relapsed AML. We evaluated the feasibility of the trial by considering cell production, patient selection, and treatment protocol.

Method

Allogeneic NK cells were produced from random healthy unrelated donors; 10 patients were selected according to the inclusion criteria and were included in two groups in case of NK cell dose escalation. Two cell infusions were given,

SUBMITTER: Ahmadvand M 

PROVIDER: S-EPMC10636850 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature